Comprehensive analysis of expression profiles of long non‑coding RNAs with associated ceRNA�network involved in gastric cancer progression

Abstract

long non-coding rnas (lncrnas) play critical roles in the development and progression of cancers. The present study aimed to identify novel lncrnas and associated micrornas (mirnas or mirs) and mrnas in gastric cancer. differentially expressed lncrnas (delncrnas) and differentially expressed mrnas (demrnas) of 6 paired gastric cancer and normal tissues were identified using microarray. The demirnas between gastric cancer and the normal control tissues were identified using mirna-seq data from cancer Genome atlas. common delncrnas from the cancer rna-Seq nexus database and circlncrnanet database were analyzed. a delncrnas-demirnas-demrnas network was constructed by target prediction. Functional enrichment analysis was employed to predict the function of demrnas in the network. The correlation between the expression of delncrnaS and demrnas in the network was analyzed. The expression levels of several genes were validated by reverse transcription-quantitative polymerase chain reaction (rT-qPcr). a total of 1,297 delncrnas, 2,037 demrnas and 171 DEmiRNAs were identified. Among the 4 lncRNAs common to the 3 datasets, prostate androgen-regulated transcript 1 (ParT1) was selected for further analysis. The analysis identified 5 DEmiRNAs and 13 DEmRNAs in the ParT1-mediated cerna network. The demrnas in the cerna network were markedly enriched in cancer-related biological processes (response to hypoxia, positive regulation of angiogenesis and positive regulation of endothelial cell proliferation) and pathways (cGMP-PKG signaling pathway, caMP signaling pathway and proteoglycans in cancer). out of the 13 demrnas, 11 were positively associated with ParT1. The downregulation of ParT1, myosin light chain 9 (MYl9), potassium calcium-activated channel subfamily M alpha 1 (KcnMa1), cholinergic receptor muscarinic 1 (cHrM1), solute carrier family 25 member 4 (SLC25A4) and ATPase na + /K + transporting subunit alpha 2 (aTP1a2) expression levels in gastric cancer was validated by rT-qPcr. on the whole, the current study identified a novel lncrna and associated mirnas and mrnas that are involved in the pathogenesis of gastric cancer that may serve as potential therapeutic targets for the treatment of gastric cancer.

Comprehensive Analysis of a ceRNA Network Identifies lncR-C3orf35 Associated with Poor Prognosis in Osteosarcoma

“…Construction of a ceRNA network contributes to reveal the occurrence and progression of cancer. Systematic analyses of ceRNA networks have been reported in lung cancer [ 28 ], gastric cancer [ 29 ], and colon cancer [ 30 ], but there have been few reports in osteosarcoma.…”

Non‑coding RNAs that regulate the Wnt/β‑catenin signaling pathway in gastric cancer: Good cop, bad cop? (Review)

“…lncRNAs act as ceRNAs to regulate GC via the Wnt/β-catenin signaling pathway. Competing endogenous RNA (ceRNA) refers to a new mechanism of interaction between RNAs; that is, ceRNA binds to miRNA via microRNA response elements (MERs) to regulate target gene expression (47,48). A large number of studies have demonstrated that ceRNAs may be inextricably linked to multiple cancers, including GC (49)(50)(51).…”

MYL9 promotes nasopharyngeal carcinoma carcinogenesis, progression and paclitaxel resistance by regulating EMT signals

“…It contains 4 exons and encodes 172 amino acids. MYL9 plays crucial function in various tumor progression and metastasis [6][7][8][9][10][11][12] . Recently, several reports show that MYL9 expression is different in various human tissues.…”